Condition: Progressive Multiple Sclerosis · Sponsor: Autolus Limited
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to highly effective therapies. Upon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion. Participants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.
This description comes directly from the study's public registry record.
Autolus Ltd · +44 (0)203 911 4385 · clinicaltrials@autolus.com
Always discuss trial participation with your own doctor first.
| Stanford University | Redwood City, California, United States | Not Yet Recruiting |
| Hospital Universitario Vall d'Hebron - PPDS | Barcelona, Spain | Active Not Recruiting |
| Hospital Universitari i Politecnic La Fe de Valencia | Valencia, Spain | Recruiting |
| Addenbrooke's Hospital | Cambridge, United Kingdom | Recruiting |
| Western General Hospital Edinburgh - PPDSE Edinburgh | Edinburgh, United Kingdom | Recruiting |
| The National Hospital for Neurology & Neurosurgery | London, United Kingdom | Recruiting |
| Royal Hallamshire Hospital | Sheffield, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07139743